---
layout: archive
title: "CV"
permalink: /cv/
author_profile: true
redirect_from:
  - /resume
---

{% include base_path %}

## Summary
Innovative Immunology Scientist with 8+ years of expertise in cell-based assays, primary/stem cell culture, and high-throughput screening for therapeutic development. Proven track record in antibody/ADC characterization, CRISPR-Cas9 gene editing, and functional immune assays (MSD/ELISA/Luminex, cytotoxicity, ADCC/ADCP). Skilled in assay development, automation, and data analysis (Prism, FlowJo, high-content imaging). Strong background in translational oncology, molecular biology, and biologics optimization. Collaborative team player with a results-driven mindset, adept at leading projects from concept to preclinical validation.

## Experience
**Senior Technician | MERUS, The Netherlands | 2023.06 – Now**  
- Designed and conducted high-quality experiments to characterize bispecific antibody responses using ELISA and flow cytometry, ensuring robust and reproducible results.  
- Developed and validated cell-based assays (2D/3D) to evaluate antibody efficacy and mechanism of action, supporting biologics development.  
- Drafted and updated SOPs and protocols, ensuring compliance with scientific and ethical standards.  
- Collaborated with cross-functional teams to align project goals with organizational objectives, contributing to strategic decision-making.  
- Presented experimental data and findings at project meetings, providing insights for the advancement of biologics development programs.  

**Senior Analyst | University Medical Center Utrecht (UMCU), The Netherlands | 2022.04 – 2023.03**  
- Optimized mass spectrometry imaging (MALDI-MSI) protocols for tumor classification and biomarker discovery, ensuring high-quality data for scientific and regulatory purposes.  
- Conducted detailed analysis of peptides, lipids, glycans, and metabolites in cancer tissues, contributing to the development of novel therapeutics.  
- Maintained meticulous digital records of experiments, ensuring traceability and compliance with scientific standards.  
- Collaborated with interdisciplinary teams to integrate scientific insights into project timelines.  

**PhD Candidate | University Medical Center Utrecht (UMCU), The Netherlands | 2017 – 2022**  
- Led research projects focused on cancer immunotherapy, including the development of monoclonal antibody-based therapies.  
- Published peer-reviewed manuscripts and presented findings at international conferences.  
- Supervised and mentored junior researchers, fostering a culture of continuous learning and collaboration.  
- Collaborated with cross-functional teams to design experiments and ensure adherence to scientific and ethical guidelines.  

**Research Assistant, MSc | Institute of Translational Medicine, Jilin University, China | 2014 – 2017**  
- Conducted in vitro and in vivo experiments to study TLR-activated plasmacytoid dendritic cells and their role in inhibiting breast cancer cell growth.  
- Developed expertise in flow cytometry, cell isolation, and mouse models, contributing to the development of novel immunotherapies.  
- Published peer-reviewed manuscripts and presented findings at scientific conferences.  

## Education
- **PhD of Infection & Immunity**, Utrecht University – University Medical Center, The Netherlands  
- **Master of Cell Biology**, Jilin University – Institute of Translational Medicine, China  
- **Bachelor of Medical Bioengineering**, Jilin University – School of Pharmacy, China  

## Skills
- **Immunoassays:** ELISA, ligand binding assays, flow cytometry  
- **Bioanalytical Techniques:** Mass spectrometry imaging (MALDI-MSI), PCR, qPCR, Western blot, 2D/3D cell-based assays  
- **Data Analysis:** Prism, Excel, FlowJo  
- **Languages:** English (Proficient), Chinese (Native), Dutch (A2)  

## Publications
1. Li S, van Dijk CGM, Meeldijk J, et al. Extracellular Granzyme K Modulates Angiogenesis by Regulating Soluble VEGFR1 Release From Endothelial Cells. *Front Oncol*. 2021;11:681967.  
2. Li S, Poolen G, van Vliet L, et al. Pediatric Medulloblastoma Express Immune Checkpoint B7-H3. *Clin Transl Oncol*. 2022;24(6):1204-1208.  
3. Voskamp MJ†, Li S†, van Daalen KR, et al. Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives. *Cancers*. 2021;13(21):5387.  
4. Li S, Wu J, Zhu S, Liu YJ, Chen J. Disease-Associated Plasmacytoid Dendritic Cells. *Front Immunol*. 2017;8:1268.  

## Key Achievements
- Successfully designed and executed high-quality experiments for ADC characterization, contributing to the development of novel biologics with improved efficacy and reduced toxicity.  
- Published multiple peer-reviewed articles on cancer immunotherapy, demonstrating expertise in monoclonal antibody research.  
- Collaborated with cross-functional teams to integrate scientific insights into project timelines, ensuring alignment with organizational goals.  
- Demonstrated strong soft skills, including communication, teamwork, and adaptability, in multicultural and multidisciplinary environments.  

## Talks
<ul>{% for post in site.talks reversed %}
  {% include archive-single-talk-cv.html %}
{% endfor %}</ul>

## Teaching
<ul>{% for post in site.teaching reversed %}
  {% include archive-single-cv.html %}
{% endfor %}</ul>
